An Open-Label Study to Characterize the Absorption, Distribution, Metabolism and Elimination of a Single Oral 14C Labeled Dose of GSK2118436 in Subjects With BRAF Mutant Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 12 Jun 2017
At a glance
- Drugs Dabrafenib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- 22 Apr 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 04 Feb 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 04 Feb 2011 Actual initiation date (Jan 2011) added as reported by ClinicalTrials.gov.